On Nov. 5, the U.S. Food and Drug Administration (FDA) approved the use of a new drug to treat head and neck cancer, the first in seven years. Called amivantamab, the drug is the first to target two growth receptors for head and neck cancer simultaneously, reducing the cancer’s ability to adapt to the treatment. The FDA granted amivantamab accelerated approval because of the promising results it showed during clinical trials, which were led by Yale School of Medicine researchers.
Barbara Burtness, MD, Anthony N. Brady Professor of Medicine at Yale School of Medicine, was the lead clinical investigator for the trials. She also guided the Yale portion of the multinational study.
We spoke with Burtness, who serves as co-leader of Yale Cancer Center’s Developmental Therapeutics Research Program, about the amivantamab approval and the future of dual-targeted cancer drugs.
Amivantamab was just approved to treat metastatic head and neck cancer, how common is that form of cancer?
Barbara Burtness, MD: Head and neck squamous cell carcinoma is the sixth most common cancer, and that probably equates to just under 70,000 cases a year. It comes in two main etiologic groups. Some diagnoses are related to human papilloma virus (HPV), and many are not. And the ones that are not are related to environmental exposures like tobacco and alcohol, or sometimes dental complications. This drug, amivantamab, is approved for the second group.
How are oncologists currently treating metastatic head and neck cancer?
Burtness: For a long time, targeting epidermal growth factor receptors (EGFR) was the only targeted therapy available for head and neck cancer. EGFR is a large molecule on the cancer cells. It’s anchored into the cell membrane and it receives growth signals, which it communicates into the cell. This causes the release of chemical signals that then lead the cell to divide and be more resistant to treatment. This receptor is very abundantly expressed on head and neck cancers, particularly the HPV-negative type.
There is a monoclonal antibody called cetuximab that targets just that receptor, and the first ever dose of cetuximab was given here at Yale in 1995. Since then, there has been an enormous amount of research to find a better therapy. When cetuximab was initially developed, it had a response rate of about 12%. More recently, when it’s given after immunotherapy, we see a response rate of 24%. But that’s still pretty disappointing, and so there’s been a lot of research into how the cell is circumventing this lack of EGFR signaling.
How does amivantamab improve on the currently available therapies?
Burtness: Amivantamab targets both EGFR and another site simultaneously. Researchers have identified what we call adaptive resistance, meaning as one part of epithelial signaling gets turned down, the cell compensates by increasing the activity of other pathways. One of the most important of these is through another receptor, but in a different family, and this is called mesenchymal-epithelial transition (MET).
There’s a lot of interest in how you can prevent the cell from compensating for EGFR inhibition by upregulating MET, and one strategy is to give an antibody that targets the ligand for MET, a protein called HGF. The better strategy has been to develop an antibody that binds to EGFR and binds to MET at the same time. Our hypothesis had been that would mean the cells couldn’t compensate in the same way. Amivantamab is a treatment that had already been approved in lung cancer, and Yale researchers wanted to test it in head and neck cancer.
What were the results of your clinical trials for amivantamab?
Burtness: We tested amivantamab in a single cohort of 102 patients who had HPV-unrelated head and neck cancer. All had previously been treated with chemotherapy and immunotherapy. In that setting, cetuximab would be expected to have a 24% response rate, and the average survival for patients is under nine months. With amivantamab we found an objective response rate of 42%, a median survival of 12 and a half months, and a large number of patients for whom their cancer was still responding to the drug at the time that the data were submitted, which is very promising.
We also found it was a tolerable treatment. It’s given as a subcutaneous injection, so patients don’t need a long IV infusion. They don’t need a lot of pre-medication, and overall, it’s well tolerated. The main side effects are rash and a lowering of the albumin. There were some infusion reactions, but it was only 15%, and they were extremely mild. We think this is a very favorable tolerability profile compared to the prior agent. This cohort study is what led to the FDA approval of amivantamab for HPV-negative head and neck cancer.
We also have data now from other cohorts of this study that show that in combination with immunotherapy and chemotherapy, the response rate is even higher. It looks like the most active single agent that we have for head and neck cancer. We’re extremely optimistic about what future studies are going to bring as well.
How did these results lead to accelerated FDA approval?
Burtness: It’s been a long time since we’ve had a drug approved for head and neck cancer. Amivantamab is both the first bispecific antibody and the first treatment to circumvent resistance to EGFR inhibition that’s been approved for head and neck cancer.
It’s not that common for the FDA to approve new drugs without a comparative trial. In general, clinical trials are comparing a standard of care to a new treatment, and it’s many hundreds of patients with a very long follow up period. I think amivantamab was approved because of both the high response rate and the very remarkable survival that these patients had. Amivantamab has also previously been used in lung cancer, so the safety data were very credible because they fit with the well-recorded experience in another disease.
What was your role in the Yale-led amivantamab clinical trials?
Burtness: I was the clinical investigator who led this cohort study. In my lab, we study EGFR inhibitor resistance, and we had been involved in testing the role of MET in adaptive resistance to EGFR inhibitors. When we had a chance to join this study, I had a leading role in designing the clinical trial and in guiding the selection criteria for a group of patients who were likely to be responsive.
I presented the study data at a national meeting in June and was the first author of the publication in the Journal of Clinical Oncology, and this data set was submitted to the FDA. We treated a large number of the patients here at Yale, although it was certainly a multi-center and international study. I am currently the principal investigator of the follow-on study, to test amivantamab plus chemotherapy plus immunotherapy, which is currently ongoing.
What comes next for amivantamab?
Burtness: I think the question in practice is going to be if a number of dual-targeted antibodies are also approved, how are physicians going to pick among them? We’re in an era of molecular medicine and precision medicine, and ideally, we would have biomarkers beyond just HPV status that would help us pick which of these agents is appropriate for which patient.
I think there’s also an open question about if a patient has progression on one of these dual-targeted therapies, is another one still going to work? We hypothesize yes, but we don’t actually have those data yet. There is still quite a lot of work that needs to be done to optimize to get as much benefit from these new drugs as we can.
We just received renewal of our specialized program of research excellence in head and neck cancer, one of only four such in the country. The program has a big focus on targeted therapy for EGFR inhibitor-resistant cancers as well as on new ways of optimizing immunotherapy.
Are Yale researchers testing any other dual-targeting drugs?
Burtness: Using the same antibody to target both sites simultaneously is one strategy, but Yale researchers have been involved in working with another dual-targeting strategy as well. The other strategy is to give cetuximab in combination with a different antibody called ficlatuzumab, which targets hepatocyte growth factor, the growth factor that activates MET signaling. We don’t yet know whether cetuximab plus ficlatuzumab will be more or less active than amivantamab.
The first small trial that we were involved in showed a response rate of 38% for cetuximab plus ficlituzumab when patients were already resistant to cetuximab alone, so that looks promising.
I also have a colleague here at Yale Cancer Center, Michael Chiorazzi, MD, PhD, assistant professor of medicine, who’s been studying the interaction between a receptor and the immune system, which is interesting because it’s thought that EGFR-resistant cancers are somewhat immune unresponsive.
